What is it about?
Increasing fluoroquinolone resistance rates limit oral empirical antimicrobial treatment options in patients with acute pyelonephritis, particularly in ambulatory settings (emergency departments, etc.).
Featured Image
Why is it important?
The study identifies patients with low predicted risk for fluoroquinolone resistance (based on clinical criteria at presentation) who may be eligible for empirical fluoroquinolone therapy, arguably without the need to adminster intravenous ceftriaxone.
Perspectives
Increasing antimicrobial resistance rates make institutional antibiograms less useful in determining empirical treatment decisions. The study offers a valuable alternative by encouraging utilization of the "patient-specific antibiogram". Each patient has a unique predicted antimicrobial resistance rate based on their individual risk factors (prior antibiotic use, etc.) regardless of national, regional or local antimicrobial resistance rates. This concept improves antimicrobial utilization and appropriateness of empirical therapy at the same time as demonstrated in this study.
Prof. Majdi Al-Hasan
University of South Carolina School of Medicine
Read the Original
This page is a summary of: Application of Fluoroquinolone Resistance Score in Management of Complicated Urinary Tract Infections, Antimicrobial Agents and Chemotherapy, February 2017, ASM Journals,
DOI: 10.1128/aac.02313-16.
You can read the full text:
Contributors
The following have contributed to this page
